The objective of this randomized controlled trial was to assess the effects of a 1-year behavioral contract intervention on immunosuppressant therapy (IST) adherence and healthcare utilizations and costs among adult renal transplant recipients (RTRs). The sample included adult RTRs who were at least 1 year posttransplant, taking tacrolimus or cyclosporine and served by a specialty pharmacy. Pharmacy refill records were used to measure adherence and monthly questionnaires were used to measure healthcare utilizations. Direct medical costs were estimated using the 2009 Medicare Expenditure Panel Survey. Adherence was analyzed using the GLM procedure and the MIXED procedure of SAS. Rate ratios and 95% confidence intervals were estimated to quantify the rate of utilizing healthcare services relative to treatment assignment. One hundred fifty RTRs were enrolled in the study. Intervention group RTRs (n ¼ 76) had higher adherence than control group RTRs (n ¼ 74) over the study period (p < 0.01). And 76.1% of the intervention group compared with 42.7% of the control group was not hospitalized during the 1-year study period (RR ¼ 1.785; 95% CI: 1.314, 2.425), resulting in cost savings. Thus, evidence supports using behavioral contracts as an effective adherence intervention that may improve healthcare outcomes and lower costs.
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Introduction
Following renal transplantation, immunosuppressant therapy (IST) adherence plays a critical role in maintaining graft function, yet the rate of IST nonadherence among renal transplant recipients (RTRs) is approximately 36% per year (1) (2) (3) . IST nonadherence is considered the leading avoidable cause of graft failure, with odds of failure sevenfold greater in nonadherent RTRs compared to adherent RTRs (4) . Given the negative consequences associated with IST nonadherence, healthcare professionals desire evidence-based interventions to facilitate and maintain adherence among RTRs, which in turn may contribute to improved outcomes and reduced healthcare utilizations and costs. However, a significant knowledge gap remains in the development and implementation of efficacious interventions to foster IST adherence.
A search of PubMed (years unlimited) revealed few published studies of interventions targeting IST adherence among adult RTRs (5) (6) (7) (8) (9) . Existing studies are hampered by ineffective interventions and/or lack of examination of outcomes related to adherence such as healthcare utilizations and costs, which were found to be associated with decreased IST adherence levels in a retrospective cohort study by Pinsky et al. (2, (6) (7) (8) (9) . Given the limits of prior published interventional studies, prospective research is needed to evaluate the effects of interventions on IST adherence and healthcare outcomes among adult RTRs.
Previous studies suggest biological, affective, cognitive, behavioral and environmental factors may impact health behaviors and act as causes of nonadherence (10) (11) (12) (13) (14) . Such findings are consistent with the tenets of social cognitive theory, which postulates that behavior is influenced by environmental and personal (biological, affective and cognitive) factors and aspects of the behavior itself (15) (16) (17) . Therefore, it would logically follow that interventions targeting a particular health behavior, such as adherence, should be designed to address environmental and personal factors. The purpose of the current study is to examine the effects of an intervention strategy based on social cognitive theory, behavioral contracting, which incorporates behavioral, personal and environmental elements to address how behavior patterns such as IST adherence are acquired and maintained. Behavioral contracting is a behavior modification technique in which a patient-specific, written agreement (contract) is developed between an individual and healthcare professional (18) . The contract identifies a target behavior and those factors that influence the behavior, and then proposes strategies to modify the target behavior to achieve a desired outcome. Advantages of contracting include: (a) patients become more active, empowered participants in their healthcare and (b) increased communication between patients and healthcare professionals (14, 19) . Behavioral contracting has demonstrated success in improving outcomes across diverse health issues (e.g. eating disorders) and patient populations (e.g. adult dialysis patients) (20) (21) (22) (23) (24) (25) (26) (27) . However, no published articles were found concerning behavioral contracting effects on IST adherence in a renal transplant population.
The theoretical premise for use of behavioral contracting as an IST adherence intervention, as described in detail by Chisholm-Burns and Spivey (28) , is that the contracting process will foster development of the RTR's self-efficacy. As an RTR's self-efficacy increases, they are likely to have greater drive and capacity to perform adherence behaviors (28, 29) . The contracting process in the proposed intervention involves patient-centered meetings between a healthcare professional and RTRs to identify, discuss and modify causes of IST nonadherence, with the goal of achieving and maintaining an optimal adherence rate. Thus, study objectives are to: (a) conduct a pilot randomized controlled trial (RCT) to assess the effects of a behavioral contract intervention on IST adherence among adult RTRs and (b) determine the effects of the intervention on direct healthcare utilizations and costs.
Materials and Methods

Study participants
Participants were recruited for this RCT from the adult renal transplant population served by Avella Specialty Pharmacy (based in the southwest United States and formerly known as the Apothecary Shops). To be included in the study, RTRs had to: (a) be at least 21 years of age (30) ; (b) be at least 1 year posttransplant to allow for stabilization of the prescribed IST regimen; (c) receive an immunosuppressant regimen that contains oral tacrolimus or cyclosporine and (d) obtain their IST from Avella for at least 1 year prior to study enrollment and during the study period.
To recruit participants, a pharmacy technician at Avella compiled a list of possible participants based on pharmacy records and inclusion criteria and contacted selected RTRs via telephone or when they visited the pharmacy. The technician briefly described the study and asked for permission to provide the study coordinator with the RTR's name and contact information. If permission was granted, the study coordinator was given this information and followed up with the possible participant via telephone. The coordinator provided further details regarding the study and asked the RTR if he/she would be interested in enrolling. If the RTR responded in the affirmative, the coordinator then mailed the enrollment packet, including informed consent documentation, to the RTR and scheduled a second telephone meeting with the RTR to review the packet. The RTR was enrolled in the study after he/she returned the signed informed consent documentation to the study coordinator following this meeting.
Upon enrollment, the study coordinator randomized participants by computerized random number sequence (generated by a biostatistician) to the intervention or control group (1:1 allocation) using a stratified block sampling approach, stratifying for gender (male, female) and race/ethnicity (non-Hispanic White, Other) in blocks of size four within a given stratum. RTRs were enrolled between January 2010 and September 2011 and followed for 1 year (the study or intervention period). All active participants completed the study by September 2012; however, refill records were collected for 3 months following the end of the study period to calculate a follow-up (postintervention) adherence rate. The study participants, coordinator and investigators were not blinded to allocation. The pharmacy technician who provided refill records as part of data collection was blinded to group allocation. The study clinical pharmacist who performed the intervention was blinded to the names of control group participants. The study was approved by the Institutional Review Board.
To calculate sample size, we projected the mean composite adherence rate for all study participants prior to study enrollment to be approximately 80 AE 15%, based on a previous study describing RTRs' IST adherence (6) . We conservatively estimated sample size using the 80% mean adherence rate for the control group. We anticipated at least a 10% increase in intervention group adherence at the end of the intervention; that is, we expected to achieve a mean adherence rate of approximately 90% in the intervention group. Under these assumptions and assuming a standard deviation of 15, to have 80% power to detect the expected difference of 10% (80% vs. 90%) at the two-tailed 5% significance level, the sample size needed to be at least 36 RTRs in each group. However, we took a conservative approach, in combination with anticipated attrition over the course of study, and increased enrollment.
Intervention
A study clinical pharmacist conducted all intervention activities. Prior to initiation of the intervention, the lead investigator trained the study clinical pharmacist on the contracting process, including purpose and theoretical background, the contract components and actively engaging the RTR in the discussion/negotiation of each contract component. During the early months of the study period, a toolbox of standardized solutions to adherence barriers was developed as an aid to the contracting process (31) . Following implementation of the intervention, the lead investigator periodically reviewed a sample of contracts and met with the study pharmacist to ensure the intervention requirements were being met.
Each RTR in the intervention group met with the study pharmacist to negotiate and sign an IST adherence contract at baseline. Each RTR in the intervention group then met with the study pharmacist at 3-, 6-and 9-months postenrollment to review his or her contract, discuss progress toward reaching the contract's goal of achieving the highest possible IST adherence, update the terms of the contract if needed and re-sign the contract for the next 3-month period. Three-month time periods were chosen because this is a common time frame used in the behavioral contracts literature (18, 24) . At the 12-month postenrollment meeting, the study pharmacist and RTR terminated the contract. The control group received standard specialty pharmacy care, which included mail or telephone reminders of monthly medication refills and an adherence 'packet' consisting of adherence-focused educational pamphlets and a pillbox (the intervention group also received standard care).
IST adherence contracts generally followed the format described by Haber and Rhodes (22) : goal setting, motivation, social support, memory techniques and problem-solving. We added a sixth component, consequences of nonadherence, as such knowledge has been identified as part of effective behavioral contracts (18, 32, 33) . The contract negotiation meetings between study pharmacist and intervention group RTR were semistructured discussions guided by the components of the contract. In the first component, the contract goal for each RTR was achieving and maintaining adherence to his/her prescribed IST regimen. The other contract components addressed individual concerns and circumstances of each RTR that were likely to influence IST adherence. Specifically, the study pharmacist and each intervention group RTR discussed and negotiated: (a) the RTR's motivation(s) for achieving IST adherence; (b) barriers that may interfere with achieving IST adherence and possible solutions to overcome barriers; (c) social support available to the RTR such as a significant other who may assist in following the IST dosing schedule; (d) tools/strategies the RTR may use to remind himself/herself to follow the IST dosing schedule and (e) possible consequences of IST nonadherence (e.g. graft loss). The aforementioned toolbox was available as a starting point for discussions of components (b) and (d) of the contract (31).
Meetings to negotiate the contract lasted an average of 20-30 min and were performed either in person or via telephone. When the RTR and the study clinical pharmacist reached agreement on each component of the contract, it was formally written up and signed by both the RTR and study pharmacist. If the meeting was held via telephone, the RTR gave the study pharmacist permission to sign the contract on the RTR's behalf. The RTR received a copy of the signed contract.
Outcome measures
At baseline, participants completed a patient characteristics questionnaire (administered via U.S. mail) that collected data such as age, gender and race/ ethnicity. Pharmacy refill records were used to measure IST adherence since they are an objective measure of the quantity of medication dispensed, are highly correlated with electronic medication monitoring, and have been used successfully in other medication adherence studies, demonstrating significant associations with health outcomes (34) (35) (36) (37) . Additionally, research has indicated that RTRs who get their IST refills filled appropriately are more likely to have desired IST serum concentrations, indicating that RTRs took their IST (12) . Refill records were obtained from Avella and assessed at baseline (after informed consent was obtained; baseline adherence was calculated using refill records data for the 1-year period prior to enrollment), 3, 6, 9 and 12 months. Refill records were also collected for 3 months following the end of the study period. Adherence was calculated by using the number of days between prescription (IST) refills. If the total number of days between refills was less than or equal to the total days' supply of IST, the participant's adherence rate was 1.0, or 100%. If the number of days between refills was greater than the days' supply, the adherence rate was calculated as follows (38) When an RTR used multiple dosage strengths of their IST, adherence rates were calculated for each strength and then averaged together to produce a single rate for a given time period.
Because our sample obtained direct medical services from a wide range of providers (e.g. physicians, hospitals, urgent care) across multiple states, we used a standardized patient reporting approach to collect direct healthcare utilizations data. A brief healthcare screening questionnaire was administered to both the intervention and control groups on a monthly basis via U.S. mail during the 1-year study period. Monthly recall periods were chosen to minimize bias and forgetfulness. A study comparing monthly patient recall to provider records found no significant differences between reports for hospitalizations and outpatient visits, lending support to the use of standardized questionnaires as a method to collect healthcare utilizations data (39) . The questionnaire collected the number of times each month a participant utilized a direct medical service, specifically, days in hospital, emergency department (ED) visit, outpatient visit (clinic, physician office) and home healthcare visit. Average number of utilizations in each of these service categories was calculated, and all direct medical costs were estimated using the 2009 Medicare Expenditure Panel Survey (MEPS), an approach generally supported in the literature (40, 41) . Total direct medical costs equal the sum of the quantity of specific services multiplied by the perunit cost of each service.
Note, graft loss is not included as an outcome in this study because the association between IST nonadherence and graft failure is well established in the literature. The intervention targeted a stable RTR population unlikely to suffer high rates of graft failure, and the sample size required to detect between-group differences in graft loss would have been prohibitive (1,2,4).
Statistical analysis
Statistical analyses were performed using SAS version 9.1 (Cary, North Carolina) and IBM SPSS Statistics 20.0 (Armonk, New York). Analyses were performed according to the intention-to-treat principle. Participant characteristics were summarized by frequencies for categorical variables, and by means and standard deviations for continuous variables. Chi-square analyses were conducted to examine independency between categorical characteristics and group assignment (intervention vs. control). Independent samples t-test was used to assess differences between group assignment and age as a continuous variable (which was normally distributed), while Mann-Whitney U-test was used to assess differences between group assignment and non-normally distributed continuous variables, annual income and months posttransplant. Spearman's rho correlations were used to assess associations between patient characteristics and baseline IST adherence. Independent samples t-tests were also used to determine if differences existed in 12-month poststudy enrollment adherence rates and healthcare utilizations based on method of intervention delivery (in person or via telephone).
Analysis of baseline characteristics and adherence (both average and over time) using chi-square (for categorical variables) and independent samples t-test or Mann-Whitney U-test (for continuous variables) did not reveal any significant differences between those lost to follow-up and those remaining in the trial. Furthermore, there was no evidence that the missing values violated the assumption of missing-at-random. Average adherence over the 1-year study period was analyzed using the GLM procedure of SAS. Only those completing the 1-year study (n ¼ 135) were included in this analysis. Initial models included the main effects of gender and ethnicity (because race and ethnicity were confounded and some racial categories were rare, ethnicity was incorporated into preliminary models instead of race), along with the interaction effects; none of these effects was significantly associated with average adherence. Preliminary analyses also indicated that adherence at baseline was associated with the number of months posttransplant and with adherence at later time periods. Therefore, the final model included both the effect of group assignment (intervention vs. control) and the continuous effect of baseline adherence. Adherence over time (i.e. refill rates at quarterly periods during 1-year study) was analyzed using a mixed model approach provided in the MIXED procedure of SAS. All subjects enrolled in the study (n ¼ 150) were included in this analysis. A linear model of adherence over time was developed using a likelihood-based estimation approach. The assumption of within-subject homogeneity of variance over time was met. However, an autoregressive covariance structure (AR(1)) was incorporated into the model to account for the influence of previous behavior on current behavior. Initial models included the main effects of ethnicity and gender, along with the interaction effects; none of these effects was significantly associated with adherence. Therefore, in addition to the random effects of subjects, the final model included only the fixed main effects of group assignment and time, along with the interaction of group assignment with time and the baseline adherence as a continuous covariate. A priori contrasts were as follows: comparisons of quarterly adherence with baseline adherence for each group (i.e. eight contrasts) and comparisons between the two groups at each assessment time (i.e. five contrasts). To control for experiment-wise Type I error rate in this analysis, a comparisonwise alpha of 0.01 was used. Because adherence (both average and over time) was affected by a ceiling effect with significant left skew, all results were verified with nonparametric approaches.
As a follow-up analysis, an independent sample t-test was conducted to compare the adherence rates of the intervention group and control group for the 3 months following the end of the study (intervention) period. This analysis included only those participants who completed the study.
In an analysis of healthcare utilizations, each type of healthcare utilization during the 1-year study period was dichotomized as 'not utilized' (zero) or 'utilized' (one). Rate ratios and 95% confidence intervals were estimated to quantify the rate of utilizing healthcare services relative to group assignment. A cost savings projection analysis was conducted to transform any detected differences between the groups in utilization rates into differences in median days of healthcare utilization per month and differences in the associated costs per month. Except as indicated above, an a priori two-tailed significance level of 0.05 was used.
Results
Of 286 screened RTRs, 150 were enrolled in the study, with 76 in the intervention group and 74 in the control group ( Figure 1) . The study population and Avella's larger patient population were similar in composition based on gender, race and age groups. Participant characteristics at baseline are displayed in Figure 2) . Intervention group RTRs also had significantly greater IST adherence compared to control group RTRs for the 3 months follow-up, postintervention period (t ¼ 2.03; df ¼ 133; p ¼ 0.044).
Regarding healthcare utilizations, Table 2 summarizes the baseline average number and average number of monthly utilizations during the study period. Approximately 59.3% of study participants did not report any hospitalizations during the 1-year study. Of those who did, the proportion of control group RTRs who had at least 1 day in the hospital during the study period was significantly greater than the proportion of intervention group RTRs (57.3% vs. 23.9%, respectively; x 2 ¼ 15.66; df ¼ 1; p < 0.001). Thus, 76.1% of the intervention group, compared with 42.7% of the control group, was not hospitalized during the 1-year study period (RR ¼ 1.785; 95% CI: 1.314, 2.425), indicating the intervention increased the probability of not being hospitalized by approximately 78%. In a cost savings projection sub-analysis, out of 100 patients who are hospitalized, approximately 29.09 would receive the intervention while 70.91 would not. Based on median number of days in hospital per month (0.333) and the average day in hospital cost of $2,000, according to MEPS, the group not receiving the intervention would have total higher costs of approximately $27,852 per month. There were no differences between groups in the proportions of RTRs who had other healthcare utilizations (i.e. ED visit, outpatient visit or home healthcare service) during the study period.
Discussion
Prior research has documented the deleterious effects of IST nonadherence on graft survival in RTRs (1,2) . Therefore, effective, evidence-based intervention strategies are needed to promote long-term IST adherence in RTRs, which in turn results in improved graft survival and may impact other outcomes such as decreased healthcare utilizations and costs. However, previous studies of interventions targeting IST adherence among adult RTRs have produced inconsistent results and have not assessed outcomes linked to adherence such as healthcare utilizations and costs (6) (7) (8) (9) . The current RCT is the first study to address this gap in the knowledge base through examination of the effects of a behavioral contract intervention on IST adherence and healthcare utilizations in an adult RTR sample. Findings of prior research indicate behavioral contracts have improved treatment adherence and related outcomes in other patient populations, e.g. hemodialysis patients (20) (21) (22) (23) (24) (25) (26) (27) . Similar patterns of increased adherence were noted in the current study. Over the course of this 1-year RCT, the intervention group experienced significantly higher rates of IST adherence compared to the control group (p < 0.01). Additionally, the intervention group continued to experience improved adherence (p < 0.05) compared to the control group in the 3 months following the end of the study/intervention period. Given the previously noted link between IST nonadherence and poor transplant outcomes, the improved adherence demonstrated by the intervention group may reduce graft dysfunction and failure.
We found the intervention not only influenced IST adherence, it also had some impact on healthcare utilizations and costs. Specifically, we found the intervention significantly increased the probability that an RTR would not be hospitalized, thereby resulting in cost savings. Because it is unclear as to whether these results are attributable to the intervention itself or changes in adherence, additional studies are needed to examine long-term utilization and cost outcomes following withdrawal of the behavioral contracting intervention.
To better understand this study's outcomes, it is necessary to step back and examine the behavioral contracting process and how it may foster better IST adherence in RTRs. As described previously, the behavioral contract is a non-legally binding document that finds its roots in social cognitive theory. During the contracting process, each RTR and the study pharmacist collaborated to identify adherence barriers faced by the RTR, such as disruptions in medication-taking routine caused by occasional workrelated travel. The RTR and study pharmacist then worked together to develop patient-centered solutions to barriers. The premise of the contracting process is that responsibilities assigned to the RTR will promote the RTR's ability to perform adherence behaviors (18, 28) . And, indeed, the findings of this RCT provide evidence suggesting that behavioral contracting improved IST adherence among RTRs who received the intervention. However, because the behavioral contract intervention was multi-faceted and involved patient-centered (individualized) collaboration between RTRs and a study pharmacist, replication may require a more general application of intervention practices.
As noted previously, more commonplace, standardized adherence solutions became part of a toolbox which assisted the study clinical pharmacist and RTR during contract negotiations (31) . Included in the toolbox are such items as reminder devices and organizational packaging. Once a solution was identified, it was written into the contract and the RTR assumed responsibility for implementing the solution. In later contract renegotiation sessions, the RTR and study pharmacist assessed what solutions did or did not work, and determined if additional solutions were needed. Thus, the behavioral contract intervention served as a mechanism by which RTRs became better prepared to tackle problems they faced in maintaining IST adherence.
Translated into practice settings, behavioral contracting would be a practical, easily employed, inexpensive strategy to encourage IST adherence in RTRs. Contract negotiation may be done in person or via telephone, and usually takes <30 min, placing minimal burden on the RTR and healthcare professional. A clinical pharmacist administered the intervention in this study, and in general, pharmacists have successfully addressed adherence issues in renal transplant and other patient populations, largely due to unique training pertaining to medication therapy and availability at the point of medication dispensing (42) . As such, we recommend the involvement of a pharmacist when using behavioral contracts in practice settings; however, future studies should assess efficacy of the intervention when administered by other healthcare professionals.
The study has limitations. The study design did not include an 'attention' control group, meaning it did not have a group that received interactions with a study pharmacist without the behavioral contract. An attention control group would have allowed us to more decisively attribute changes in adherence to the behavioral contract. Future studies involving the behavioral contract intervention should consider including an attention control group to address this issue. An additional limitation is that we did not employ multiple study pharmacists to perform the intervention. Therefore, we are unable to determine if the study pharmacist had some unique quality that promoted adherence among intervention group RTRs which could not be replicated by another healthcare professional attempting to perform the intervention. However, the use of multiple study pharmacists could also have introduced the confounding factor of inconsistent intervention implementation. There are also limitations to all adherence measures, including pharmacy refill records. Limitations of pharmacy refill records include that their accuracy may be affected by dosage changes and that they do not indicate whether medication is actually consumed according to the prescribed dosing schedule (43) (44) (45) . However, as previously stated, prior research has found that RTRs who appropriately refill their IST are more likely to have desired IST serum concentrations, and therefore we believe pharmacy refill records are a reliable and valid measure of IST adherence (12) . Another limitation is that we were unable to collect utilization and cost data directly, as our sample had multiple payers and sought healthcare services from a wide range of providers and institutions across multiple states. Attempts at direct data collection would have been difficult from a logistical and regulatory (e.g. remaining HIPAA compliant) standpoint. Therefore, we relied on a standardized monthly reporting approach to collect utilization data and used cost averages reported by MEPS to estimate costs and cost savings (41) . Self-report of utilization data is generally considered a valid method of data collection, as comparisons of monthly patient recall to provider records found no significant differences for hospitalizations and outpatient visits (39) . Likewise, a review of the research capacity of MEPS concluded that due to its range of data, MEPS is 'well suited' to support analyses of healthcare costs (40) . As such, our data are likely an accurate representation of healthcare utilizations and cost savings. A further limitation is that although the behavioral contract intervention was designed to promote self-efficacy, selfefficacy was not measured during the study period because changes in IST adherence was the primary variable under consideration. Future studies involving the behavioral contract intervention should include in their design the measurement and assessment of changes in self-efficacy. Lack of empirical assessment of the study pharmacist's fidelity to and consistent application of intervention procedures constitutes an additional limitation. Future behavioral contract intervention studies should consider including a component to empirically evaluate the performance of the healthcare professional administering the intervention. Another limitation is that, because the study sample was largely recruited in the southwest United States, racial/ethnic demographics are more representative of the Southwest population than the general U.S. renal transplant population, although female RTRs are somewhat overrepresented due to the stratified sampling approach (Table 3 ) (46) . As a result, generalizability of findings may be limited to groups that are well represented in the study, namely White and Hispanic RTRs. However, greater inclusion of Hispanic RTRs is a unique characteristic of the current study, as Hispanic representation is not typical of previously published adherence intervention studies. This is the first study to evaluate the efficacy of behavioral contracting as an intervention to improve IST adherence among RTRs. Findings indicate the intervention successfully increased IST adherence, and may have also contributed to decreased likelihood of being hospitalized and associated costs. On the basis of the evidence provided by this RCT, we conclude behavioral contracting is a promising adherence intervention in RTRs that may positively impact healthcare outcomes. Future studies involving the behavioral contract as an IST adherence intervention among RTRs should examine the individual contributions of each facet of the intervention (e.g. the behavioral contract itself vs. the interaction with the study pharmacist) to better understand those elements that most directly impact adherence and healthcare outcomes. The Organ Procurement and Transplantation Network, from which the southwest U.S. and national data figures were calculated, does not separate race and ethnicity.
